Serotonin 5-HT2 Receptor Antagonists
"Serotonin 5-HT2 Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to but do not activate SEROTONIN 5-HT2 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT2 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more specific 5-HT2 receptor subtypes.
| Descriptor ID |
D058830
|
| MeSH Number(s) |
D27.505.519.625.850.850.200 D27.505.696.577.850.850.200
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Serotonin 5-HT2 Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Serotonin 5-HT2 Receptor Antagonists".
This graph shows the total number of publications written about "Serotonin 5-HT2 Receptor Antagonists" by people in this website by year, and whether "Serotonin 5-HT2 Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Serotonin 5-HT2 Receptor Antagonists" by people in Profiles.
-
Evaluation of Isolated Vascular Response to 5HT1A, 5HT1B1D & 5HT2A Receptors Agonist & Antagonist in Chronic Endotoxemic Rats. Drug Res (Stuttg). 2019 Jun; 69(6):352-360.
-
5-HT2 and 5-HT2B antagonists attenuate pro-fibrotic phenotype in human adult dermal fibroblasts by blocking TGF-ß1 induced non-canonical signaling pathways including STAT3 : implications for fibrotic diseases like scleroderma. Int J Rheum Dis. 2018 Dec; 21(12):2128-2138.
-
Synthesis and biological evaluation of a series of novel pyridinecarboxamides as potential multi-receptor antipsychotic drugs. Bioorg Med Chem Lett. 2018 02 15; 28(4):606-611.
-
Specific depressive symptoms predict remission to aripiprazole augmentation in late-life treatment resistant depression. Int J Geriatr Psychiatry. 2018 02; 33(2):e330-e335.